神經內分泌腫瘤治療市場：依藥物類別、按適應症、按配銷通路、按地區

Neuroendocrine Tumor Treatment Market, By Drug Class, By Indication, By Distribution Channel, and By Region

出版日期: 2023年10月23日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年，全球神經內分泌腫瘤治療市場規模將達32.4億美元，預測期內（2023-2030年）年複合成長率為6.2%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	32.4億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	6.20%	2030年市場規模預測	49.4億美元

圖 1. 2023 年神經內分泌腫瘤治療的全球市場佔有率(%)（依藥物類別）

神經內分泌腫瘤 (NET) 是一種始於人類神經內分泌系統特化細胞的癌症。這些細胞具有產生荷爾蒙的內分泌細胞和神經細胞的特徵。神經內分泌系統的細胞存在於全身器官中並控制許多身體功能。神經內分泌腫瘤相對罕見，可發生在身體的任何部位，但最常見於肺部、闌尾、小腸、直腸和胰臟。神經內分泌腫瘤 (NET) 可以是無功能性（無症狀）或功能性（有症狀）的。功能性 NET 的症狀因產生的荷爾蒙而異，但非功能性 NET 經常在因其他原因進行的影像檢查中被發現。有些神經內分泌腫瘤具有侵襲性且生長迅速，而有些則生長緩慢。全球神經內分泌腫瘤治療市場預計在未來年度將顯著成長。這種成長是由多種因素推動的，包括神經內分泌腫瘤盛行率的增加、診斷技術的進步以及新的有效治療方法的發展。神經內分泌腫瘤的治療通常涉及手術、放射線治療和藥物治療的組合。要進行的特定治療類型通常取決於腫瘤的型態和階段以及患者的一般狀況。近年來，針對 NET 的標靶治療的開發顯著增加。這些治療方法特異性針對癌細胞並最大限度地減少對健康細胞的損害。

市場動態

NET，有時稱為類癌，可以有症狀，也可以無症狀，如果沒有外在體徵或症狀，可能多年都未被發現。 NET 的一般特徵是能夠產生引起此症候群的胜肽。因此，增加治療神經內分泌腫瘤患者的研發活動預計將在預測期內推動市場成長。例如，2022 年 3 月，商業階段製藥公司Amyrt Pharma plc 啟動了Mycapssa（奧曲肽膠囊）的生物利用度研究，該研究計劃在治療與神經內分泌腫瘤(NET) 相關的類癌症狀的3 期試驗中取得成功。此外，根據與上述相同的資訊來源，根據這項研究，高達 80 mg 的 Mycapssa 劑量顯示出預期的劑量比例和生物利用度，以及可接受的安全性和耐受性。

研究的主要特點

本報告對全球神經內分泌腫瘤治療市場進行了詳細分析，並提出了以2022年為基礎的預測期（2023-2030）的市場規模和復合年度（年複合成長率）。
它還強調了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球神經內分泌腫瘤治療市場的主要參與者進行了分析。
本研究涵蓋的主要企業包括輝瑞公司、諾華公司、Ispen、Advanced Accelerator Inductions、Tarveda Therapeutics、Progenics Pharmaceuticals, Inc.、Hutchison Medipharma Limited、Dauntless Pharmaceuticals Inc.、Exelixis, Inc.。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場經營團隊和行銷策略做出明智的資訊。
全球神經內分泌腫瘤治療市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球神經內分泌腫瘤治療市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 3.24 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.20%	2030 Value Projection:	US$ 4.94 Bn

Neuroendocrine tumors (NETs) are a type of cancer that begins in the specialized cells of the body's neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body's organs and help control many of the body's functions. NETs are relatively rare and can occur anywhere in the body, but most commonly occur in the lungs, appendix, small intestine, rectum, and pancreas. Neuroendocrine tumors (NETs) can be non-functioning (without symptoms) or functional (with symptoms). Symptoms of functional NETs depend on which hormone is produced, while non-functioning NETs are often detected during imaging tests performed for other reasons. Some NETs are aggressive and fast-growing, while others are slow-growing. The global neuroendocrine tumor treatment market is expected to grow significantly in the coming years. This growth is driven by several factors, including an increase in the prevalence of neuroendocrine tumors, advancements in diagnostic technologies, and the development of new and effective therapies. The treatment of NETs typically involves a combination of surgery, radiation therapy, and medications. The specific type of treatment used is frequently determined by the tumor's form and stage as well as the patient's general condition. In recent years, there has been a significant increase in the development of targeted therapies for NETs. These therapies work by specifically targeting cancer cells, which can help minimize damage to healthy cells.

Market Dynamics

NETs are sometimes called carcinoid tumors, can be symptomatic or asymptomatic and may go undiscovered for years if there are no outward indications or symptoms. NETs are generally characterized by their ability to produce peptides that lead to their syndromes. Thus, increasing research and development activities for the treatment of patients suffering from neuroendocrine tumors is expected to foster market growth over the forecast period. For instance, in March 2022, Amyrt Pharma plc, a commercial stage pharmaceutical company, reported successful bioavailability study for Mycapssa (octreotide capsules) in a planned Phase 3 study in the treatment of carcinoid symptoms associated with neuroendocrine tumor (NET). Furthermore, from the same source above, according to the study, Mycapssa dosages up to 80mg showed the anticipated dose proportionality and bioavailability along with an acceptable safety and tolerability profile.

Key features of the study:

This report provides an in-depth analysis of the global neuroendocrine tumor treatment market and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuroendocrine tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Indications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine tumor treatment market

Detailed Segmentation:

By Drug Class:
- Somatostatin Analogs
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others
By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Pfizer Inc
- Novartis AG
- Ispen
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Trends
Recent Launches and Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Neuroendocrine Tumor Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Neuroendocrine Tumor Treatment Market, By Drug Class, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Neuroendocrine Tumor Treatment Market, By Indication, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Gastrointestinal NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Lung NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Pancreatic NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Neuroendocrine Tumor Treatment Market, By Distribution Channel, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

8. Global Neuroendocrine Tumor Treatment Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa